ly3298176 tirzepatide Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Tirzepatide (LY3298176) Datasheet DC Chemicals

[DOI] [PubMed] 74.Zinman B, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, Tarp-Johansen MJ, Araki E, PIONEER 8 Investigators

Every other industry waits for regulators

Many patients can begin their medical weight loss journey through secure telehealth consultations, allowing them to discuss treatment options with a licensed provider from anywhere in Florida

Typically, patients of our weight loss program in San Jose, California who start FDA-approved GLP-1 medications like Ozempic and Wegovy lose an average 15% of their weight when combined with diet and exercise

189191 Additional considerations include appropriate dose titration, renal function monitoring, and review of polypharmacy, as outlined in Table 2